• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ZIVO

    Zivo Bioscience Inc.

    Subscribe to $ZIVO
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Keego Harbor, Michigan.

    IPO Year:

    Exchange: NASDAQ

    Website: zivobioscience.com

    Peers

    $AYTU
    $DARE
    $YTEN

    Recent Analyst Ratings for Zivo Bioscience Inc.

    DatePrice TargetRatingAnalyst
    12/15/2021$9.00Buy
    Maxim Group
    See more ratings

    Zivo Bioscience Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Zivo Bioscience with a new price target

      Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00

      12/15/21 10:56:47 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Zivo Bioscience Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yaldoo Laith L bought $49,983 worth of shares (3,488 units at $14.33) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      6/16/25 5:04:19 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Maggiore Christopher D. sold $325 worth of shares (20 units at $16.25), decreasing direct ownership by 0.00% to 507,000 units (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/9/25 9:42:34 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yaldoo Laith L bought $176,682 worth of shares (10,080 units at $17.53) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/4/25 8:23:32 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 5 filed by Strome Mark E

      5 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      1/23/25 7:48:25 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Strome Mark E acquired $629,000 worth of shares (34,000 units at $18.50) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      1/21/25 8:00:23 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yaldoo Laith L was granted 11,122 shares, increasing direct ownership by 2% to 542,111 units (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      1/3/25 4:40:08 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Maggiore Christopher D. was granted 8,577 shares, increasing direct ownership by 2% to 507,020 units (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      1/3/25 4:27:12 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Masterson Nola E was granted 8,882 shares, increasing direct ownership by 7% to 130,906 units (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      1/3/25 4:25:58 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Cornell Alison A was granted 9,797 shares, increasing direct ownership by 4% to 267,772 units (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      1/3/25 4:24:51 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Strome Mark E bought $1,514,250 worth of shares (75,000 units at $20.19) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      12/31/24 6:47:29 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care